Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Xilio Therapeutics Inc. Common Stock
XLO | US
8.51
USD-0.05
-0.58%
XLO | US
About Xilio Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
8.51
Open
8.52
High
8.81
Low
8.46
Xilio Therapeutics Inc. a clinical-stage biotechnology company discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101 an investigational Fc-enhanced tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs which comprises XTX202 a tumor-activated IL-2; and XTX301 an investigational tumor-activated engineered IL-12 molecule. Xilio Therapeutics Inc. was founded in 2016 and is headquartered in Waltham Massachusetts.
View LessXLO | US
Risk
56.1
Sharpe
-0.12
Luna's Score
54/100
Recommendation
Hold
Luna says (XLO | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
29.6%1 month
56.1%3 months
51.9%6 months
50.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.02
Debt to equity
0.26
Debt to assets
0.10
Ent. to EBITDA
-0.11
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-64.91M
MarketCap
374.04M
MarketCap(USD)
374.04M
Div. yield
-
Op. margin
-622.57
Erngs. growth
-
Rev. growth
-
Ret. on equity
-130.03
Short ratio
0.68
Short perc.
0.38
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.18
Range1M
8.79
Range3M
8.79
Volumes: Market Activity
Rel. volume
0.09
Price X volume
107.65K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.11 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.02 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 51.90 | - | Lower Risk |
| Debt to Equity | 0.26 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 374.04M | - | Emerging |
